Medical Systems - Adv Dev

Abstract

This program element (PE) funds development of medical materiel at the start of an official program of record, within the early system integration portion of the System Development and Demonstration phase of the acquisition life cycle using 6.4 funding. Program efforts support transition of promising Science and Technology candidate medical technologies (drugs, vaccines, medical devices, diagnostics, and mechanisms for detection and control of disease carrying insects) to larger scale testing in humans for safety and effectiveness. Programs are aligned to meet Future Force (F2) requirements stressed within concept documents and organizational structures. The PE provides funding for Food and Drug Administration (FDA) regulated human clinical trials to gain additional information about safety and effectiveness on the path to licensure for use in humans. The Projects supported by this PE are: (PROJ 836) funds the demonstration and validation of medical products for enhanced combat casualty care and follow-on care, including rehabilitation. This project also funds the human clinical trials that test the safety and effectiveness of biologics, devices and demonstration. Clinical trials are conducted in accordance with U.S. Food and Drug Administration (FDA) regulations. Products from this project will transition to 832. (PROJ 808) funds development of candidate medical countermeasures for infectious diseases of military relevance. Efforts include vaccines, drugs, diagnostic kits/devices, and insect control measures. These funds support human clinical efficacy trials of the drug/vaccine in a larger group that are designed to assess performance and to continue safety assessments in a larger group of volunteers. Products from this project will transition to 849. (PROJ 811) funds the development of military relevant human immunodeficiency virus (HIV) medical countermeasures. It provides funding for planning and conducting of human clinical trials in a group of healthy volunteers to assess the drug/vaccine for safety, tolerability, how the drug/vaccine is distributed, metabolized, and excreted from the body, and investigate the appropriate dose for therapeutic use. Products from this project will transition to Project 812. (PROJ VS7) program upgrades, retrofits, trains, and sustains the 256 Medical Evacuation legacy helicopters that continue to play a major role in Iraq and Afghanistan. The force design will increase the number of air frames in the force from 12 to 15 aircraft for 37 MEDEVAC companies to better meet operation needs. Products from this project will transition to VS8. This program is managed by U.S. Army Medical Materiel Development Activity (USAMMDA) and U.S. Army Medical Materiel Agency (USAMMA) of the US Army Medical Research and Materiel Command

Open PDF

Document Details

Document Type
R2 Budgetary Justification
Publication Date
Oct 01, 2012
Source ID
0603807A_4_2040_PB_2012
Change Summary Explanation
Service Agency Name
Army

Entities

Organizations

  • United States Army

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Acquisition
  • Aircrafts
  • Anesthesia
  • Blood
  • Brain Injuries
  • Clinical Trials
  • Combat Casualty Care
  • Combat Support Hospitals
  • Cost Analysis
  • Health Services
  • Infectious Diseases
  • Materials
  • Medical Evacuation
  • Test And Evaluation
  • Therapy
  • Vaccines
  • Warfare

Fields of Study

  • Medicine

Readers

  • Infectious Disease/Epidemiology
  • Military Science and Technology Research and Modernization.
  • Trauma or Military Medicine

Technology Areas

  • Biotechnology

Related Documents